DENVER--(BUSINESS WIRE)--Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP) (the “Company”), a biopharmaceutical and medical device company focused on infectious disease and dermatology, today announced that it will be presenting data on its CeraShield™ antimicrobial medical device coating at the upcoming Medtech Insight conference “Investment In Innovation (In3) Europe: Bridging European and U.S. Medical Device Innovators, Investors and Companies.” The conference will be held on April 28- 29, 2008 in Paris, France. The Company will present data from recent testing comparing the in vitro antimicrobial efficacy of developmental CeraShield™ coated urinary silicone catheters with commercially available urinary catheters that contain either silver or nitrofurazone when challenged with daily doses of E.coli, the most common pathogen associated with urinary tract infections. The use of urinary catheters is linked to the development of urinary tract infections which add over $450 million in hospital costs annually in the United States.
